{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'adjusting standard anti-diabetic therapy in diabetic subjects. Importantly, hyperglycemia in all', 'teprotumumab-treated subjects was at Baseline levels after the end of the Treatment Period.', '7.1.3.4.2 Efficacy', 'The TED01RV study demonstrated that subjects with active moderate-to-severe TED', 'experienced statistically significant and clinically meaningful results in the proportion of', 'responders at Week 24 in the teprotumumab group relative to placebo (69% [29/42 subjects]', 'versus 20% [9/43 subjects], respectively; p < 0.001). Therapeutic effects were rapid, with', 'responder rates in the teprotumumab group significantly greater than those in the placebo group', 'at Weeks 6, 12, and 18 (all < 0.001). Specifically, the proptosis component of the responder', 'analysis showed a mean (standard error) reduction of 2.46 mm (0.20) in the teprotumumab group', 'compared to 0.15 mm (0.19) in the placebo group at Week 24 (p < 0.001).', 'The secondary endpoints (QoL, proptosis, and CAS as continuous variables) supported the', 'primary analysis conclusion that teprotumumab was superior to placebo in the treatment of this', 'population.', 'In conclusion, for subjects with active ophthalmopathy, teprotumumab was more effective than', 'placebo in reducing proptosis and the CAS.', '7.1.3.4.3 Pharmacokinetics', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 53 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 54 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '7.1.3.4.4 Pharmacodynamic Markers', '7.1.3.4.5 Safety', '7.1.3.4.5.1 River Vision TED01RV Study', 'Treatment-emergent AEs (TEAEs) in TED01RV that were reported for at least 5% of the', 'subjects in the teprotumumab group and had a greater frequency than that in the placebo group', 'are shown in Table 7.2. The majority of AEs were mild, required no treatment, and resolved', 'while subjects remained on drug. Hyperglycemia, which was monitored by assessing blood', 'glucose and HbAlc, was the only AE clearly identified as related to study drug.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 55 of 117']\n\n###\n\n", "completion": "END"}